Elicio Therapeutics Statistics
Total Valuation
ELTX has a market cap or net worth of $42.46 million. The enterprise value is $25.55 million.
| Market Cap | 42.46M |
| Enterprise Value | 25.55M |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ELTX has 28.31 million shares outstanding. The number of shares has increased by 33.59% in one year.
| Current Share Class | 28.31M |
| Shares Outstanding | 28.31M |
| Shares Change (YoY) | +33.59% |
| Shares Change (QoQ) | +36.62% |
| Owned by Insiders (%) | 20.02% |
| Owned by Institutions (%) | 21.86% |
| Float | 21.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.24 |
| P/TBV Ratio | 2.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.74.
| Current Ratio | 3.43 |
| Quick Ratio | 3.11 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.46 |
Financial Efficiency
Return on equity (ROE) is -315.32% and return on invested capital (ROIC) is -92.64%.
| Return on Equity (ROE) | -315.32% |
| Return on Assets (ROA) | -70.57% |
| Return on Invested Capital (ROIC) | -92.64% |
| Return on Capital Employed (ROCE) | -129.19% |
| Weighted Average Cost of Capital (WACC) | 13.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ELTX has paid $55,000 in taxes.
| Income Tax | 55,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.68% in the last 52 weeks. The beta is 2.00, so ELTX's price volatility has been higher than the market average.
| Beta (5Y) | 2.00 |
| 52-Week Price Change | -83.68% |
| 50-Day Moving Average | 1.81 |
| 200-Day Moving Average | 6.45 |
| Relative Strength Index (RSI) | 40.09 |
| Average Volume (20 Days) | 331,732 |
Short Selling Information
The latest short interest is 1.84 million, so 6.49% of the outstanding shares have been sold short.
| Short Interest | 1.84M |
| Short Previous Month | 1.70M |
| Short % of Shares Out | 6.49% |
| Short % of Float | 8.65% |
| Short Ratio (days to cover) | 6.67 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.33M |
| Pretax Income | -35.68M |
| Net Income | -35.74M |
| EBITDA | -38.16M |
| EBIT | -38.33M |
| Earnings Per Share (EPS) | -$1.80 |
Balance Sheet
The company has $30.90 million in cash and $13.99 million in debt, with a net cash position of $16.91 million or $0.60 per share.
| Cash & Cash Equivalents | 30.90M |
| Total Debt | 13.99M |
| Net Cash | 16.91M |
| Net Cash Per Share | $0.60 |
| Equity (Book Value) | 18.85M |
| Book Value Per Share | 0.67 |
| Working Capital | 24.11M |
Cash Flow
In the last 12 months, operating cash flow was -$36.97 million and capital expenditures -$16,000, giving a free cash flow of -$36.99 million.
| Operating Cash Flow | -36.97M |
| Capital Expenditures | -16,000 |
| Depreciation & Amortization | 162,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -36.99M |
| FCF Per Share | -$1.31 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -33.59% |
| Shareholder Yield | -33.59% |
| Earnings Yield | -120.11% |
| FCF Yield | -87.69% |
Analyst Forecast
The average price target for ELTX is $13.00, which is 766.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.00 |
| Price Target Difference | 766.67% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |